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Patients with cirrhosis of liver are at risk of developing serious bacterial infections due to altered immune defenses. Despite the
widespread use of broad spectrum antibiotics, bacterial infection is responsible for up to a quarter of the deaths of patients with
liver disease. Cirrhotic patients with gastrointestinal bleed have a considerably higher incidence of bacterial infections particularly
spontaneous bacterial peritonitis. High index of suspicion is required to identify infections at an early stage in the absence of
classical signs and symptoms. Energetic use of antibacterial treatment and supportive care has decreased the morbidity and
mortality over the years; however, use of antibiotics has to be judicious, as their indiscriminate use can lead to antibiotic resistance
with potentially disastrous consequences. Preventive strategies are still in evolution and involve use of antibiotic prophylaxis
in patients with gastrointestinal bleeding and spontaneous bacterial infections and selective decontamination of the gut and
oropharynx.
1.Introduction
Bacterialinfectionsareacommon,recurrentcomplicationof
cirrhosis associated with poor outcome [1]. Decompensated
cirrhosis has more frequent episodes of infections than com-
pensated cirrhosis. Once infection develops, renal failure,
shock, and encephalopathy may follow, which adversely af-
fect survival. Recent prospective studies have shown that 32–
34% of cirrhotic patients develop a bacterial infection either
at the time of admission or later during their hospitalization
[2]. Among cirrhotic patients being admitted for gastroin-
testinal hemorrhage, the rate of infection is even higher at
an estimated 45% and has been shown to be associated with
failure to control bleeding and with early variceal rebleeding
[3–7].Thesenumberscontrastsharplywiththe5–7%overall
infection rates for the general population and emphasize
the concept of cirrhosis as an acquired immunodeﬁcient
state. The development of infection in cirrhosis is associated
with a signiﬁcantly higher mortality that has been shown
to be independent of the severity of liver disease [2, 8–10].
In fact, the in-hospital mortality of cirrhotic patients with
infection is approximately 15%, more than twice that of
patients without infection. More importantly, infection is
directly responsible for 30–50% of deaths in cirrhosis [11].
The mechanisms of increased susceptibility to infections
in cirrhosis are unclear. Numerous mechanisms implicated
in altered and diminished immunity include increased
shunting of blood away from the liver, qualitative dysfunc-
tion of the reticuloendothelial system, decreased opsonisa-
tion capacity of the ascitic ﬂuid, and increased intestinal
permeability of bacteria and associated endotoxins [12]. It
has been suggested that there is a role for deﬁciencies in
C3 and C4, downregulation of monocyte human leukocyte
antigen-DR expression (and subsequent impaired antigen
presentation ability), and impairment of macrophage Fcγ-
receptor-mediated clearance of antibody-coated bacteria.
Patients with alcoholic cirrhosis have depressed neutrophil
phagocytic and intracellular killing of microorganisms [13,
14].
The most common infections in cirrhotics are sponta-
neous bacterial peritonitis (SBP) (25%), followed by urinary
tract infection (20%), pneumonia (15%), bacteremia fol-
lowing a therapeutic procedure, cellulitis, and spontaneous
bacteremia [1]. Infections are culture positive in 50%–
70% of cases. The causative organisms of community-ac-
quired infection are Gram-negative bacilli (GNB), especially
Escherichia coli, in about 60%, Gram-positive cocci (GPC) in2 International Journal of Hepatology
about 30%–35%, and mixed in the last 5%–10%. Nosoco-
m i a li n f e c t i o n sb e h a v ed i ﬀerently with 60% GPC and 30%–
35% positive for GNB, as a result of the use of therapeutic
procedures and previous antibiotic therapies [15]. Beside
Escherichia coli, the most frequently isolated bacteria are
Staphylococcusaureus,Enterococcusfaecalis, andStreptococcus
pneumoniae. In cirrhotics less virulent organisms cause
infections suggesting that, in advanced cirrhosis, bacteria do
not need to develop strategies to circumvent host defenses
and invade the host [16]. While GNB notably Escherichia coli
are the causative agents in spontaneous bacterial peritonitis
(SBP) and urinary tract infections, Gram-positive bacteria
(GPB) predominate in pneumonia (Streptococcus pneumo-
niae) and procedure-associated bacteremia (Staphylococcus
aureus). Fungal infections especially Candida species are
involved in up to 15% of severe sepsis in cirrhosis [17].
Most of the available information on bacterial infections
in cirrhosis refers to SBP, an entity that is essentially unique
to the cirrhotic patient and shares its pathogenesis and man-
agementwithspontaneousbacteremiaandspontaneousbac-
terialempyema.Gram-positiveinfectionsincirrhosissuchas
pneumonia or secondary bacteremia are managed according
to conventional criteria.
2.SpontaneousBacterial Peritonitis
Spontaneous bacterial peritonitis (SBP), that is, sponta-
neous infection of ascitic ﬂuid without any apparent intra-
abdominal source of infection, is the most characteris-
tic infective complication in cirrhosis [18]. The one-year
probability of development of the ﬁrst SBP in cirrhotic
patients with ascites is approximately 10%. This probability
is higher in cirrhotic patients with coexisting gastrointestinal
bleed, low ascitic ﬂuid protein concentration (<1g/dl),
and/or severe hepatic insuﬃciency [19–21]. When ﬁrst
described, the mortality of SBP exceeded 90%; however, with
early recognition of the disease and prompt and appropriate
antibiotic therapy, mortality has been reduced to around
30% [22].
As SBP may pass unrecognized, diagnostic paracentesis
should be done in all cirrhotics with ascites on admission
to hospital, in-patients with ascites who develop signs of
sepsis, hepatic encephalopathy, renal impairment, or altered
gastrointestinal motility, and all ascitic patients with a
gastrointestinal bleed [23]. SBP is diagnosed with an ascites
polymorphonuclear cell count >250/mm3, independent of
ascites bacteriological culture results [24]. The use of reagent
strips may provide a rapid bedside diagnosis of SBP. The
test is a quick, safe, and relatively inexpensive screening tool
that can be employed at the bedside while awaiting formal
cell count and culture analysis. The reagent strip checks for
leukocyte esterase activity of activated granulocytes. High
numbers of activated leukocytes result in increased hydrol-
ysis of the tested compound and generate a color change
on the strip. The results of 8 trials using diﬀerent types of
strips are available [25–32]. Most trials include a very small
number of ascites samples with a PMN count >250/mm3,
and,therefore,althoughmediansensitivityresultsare ∼85%,
there is lack of suﬃcient data for its use in clinical practice
unless larger trials validate these observations.
2.1. Treatment of Spontaneous Bacterial Peritonitis. Cefo-
taxime is the most widely studied cephalosporin in patients
with SBP and is suitable for empirical therapy for this con-
dition. Prior to 1985, treatment of the condition was subop-
timal. A landmark study comparing the combination ampi-
cillin/tobramycin with cefotaxime showed that cefotaxime
signiﬁcantly increased the resolution of bacterial infections,
includingSBPincirrhoticpatients[33].Followingthisstudy,
cefotaxime is considered as one of the ﬁrst-choice antibiotic
therapies in the empirical treatment of SBP in patients with
cirrhosis. Recent studies have demonstrated that ceftriaxone
is highly eﬀective in the treatment of SBP, with a resolution
rate of 100% and a hospital mortality rate of 30% [34, 35].
The combination of amoxicillin and clavulanic acid has
also shown to be as eﬀective and safe as cefotaxime in the
treatment of SBP [36]. The use of ﬂuoroquinolones for
treatment of SBP has shown similar eﬃcacy. Oral oﬂoxacin
has been shown to be as eﬀective as intravenous cefotaxime
in the treatment of patients with “uncomplicated” SBP,
deﬁnedbytheabsenceofgastrointestinalhemorrhage,severe
encephalopathy, ileus or septic shock, and a creatinine
<3mg/dL[37].
2.2. Spontaneous Bacterial Peritonitis Prophylaxis. The gut
appears to be the main source of bacteria that cause SBP
and other Gram-negative infections in cirrhosis. Given that
SBP is thought to result from the translocation of enteric
GNB, the ideal agent should be safe, aﬀordable, and ef-
fective at eliminating GNB from the gut while preserving
the protective anaerobic ﬂora. Bacterial translocation, the
phenomenon by which viable microorganisms from the
intestinal lumen migrate to mesenteric lymph nodes and
other extraintestinal sites, has been postulated as one of the
main mechanisms in the pathogenesis of these infections.
Therefore, prophylaxis has been based on the oral adminis-
tration of nonabsorbable or poorly absorbed antibiotics that
will eliminate or reduce the concentration of Gram-negative
gut bacteria without aﬀecting Gram-positive organisms or
anaerobes,theso-calledselectiveintestinaldecontamination.
Giventhehighcostandinevitableriskofdevelopingresistant
organisms,theuseofprophylacticantibioticsmustbestrictly
restricted to those at highest risk of SBP.
Long-term administration of orally administered nor-
ﬂoxacin, a poorly absorbed quinolone, has been shown to
produce a marked reduction of GNB from the fecal ﬂora
of cirrhotic patients with no signiﬁcant eﬀects on GPC or
anaerobic bacteria [38]. The development of infections by
quinolone-resistant organisms is the main complication of
long-term norﬂoxacin prophylaxis. A recent study showed
clear diﬀerences in the type of bacteria causing infections
in cirrhotic patients on chronic quinolone prophylaxis:
while 67% of infections in untreated cirrhotic patients
were due to Gram-negative organisms, infections in patients
receiving quinolone prophylaxis were mostly due to Gram-
positive organisms (79%). This study also showed the emer-
g e n c eo fs e v e r en o s o c o m i a lStaphylococcal infections due toInternational Journal of Hepatology 3
methicillin-resistant strains [39]. Therefore, SBP prophylaxis
should be considered only in high-risk populations or the
patients awaiting liver transplantation.
Three patient populations considered at high risk and
in whom prophylactic antibiotic therapy has been recom-
mended are patients with prior history of SBP, patients ad-
mittedwithgastrointestinalbleed,andpatientswithlowtotal
protein content in ascitic ﬂuid.
2.2.1. Prophylaxis in Patients with a Previous Episode of Spon-
taneous Bacterial Peritonitis. The 1-year and 2-year prob-
abilities of survival after an episode of SBP are of 30–
50% and 25–30%, respectively, [18]. Therefore, patients
recovering from an episode of SBP should be considered
as potential candidates for liver transplantation. As such,
it is imperative to initiate long-term prophylactic therapy
in all patients with prior history of SBP. Norﬂoxacin, a
poorly absorbed quinolone selective to GNB, was shown to
decrease the 1-year probability of SBP from 68% to 20%
when dosed at 400mg daily. In this study, the probability
of developing SBP speciﬁcally from GNB was reduced from
60% to 3% [40]. Subsequently economic analysis studies
have shown substantial cost savings in initiating prophylactic
therapy in patients with a prior episode of SBP rather than
treating at time of diagnosis [41, 42]. Another trial using oral
trimethoprim/sulfamethoxazole also showed eﬃcacy in the
prevention of SBP. It can be used as an alternative in patients
who are unable to take or develop resistance to quinolones
[43]. Prophylactic therapy should be instituted after the
completion of antibiotics for acute SBP and continued until
death, transplant, or resolution of ascites [44].
2.2.2. Prophylaxis in the Setting of Gastrointestinal Bleeding.
All cirrhotic patients who develop an upper gastrointestinal
bleed are at risk of a variety of bacterial infections, including
SBP, within the ﬁrst few days following the bleed. Bacteria
of enteric origin are most commonly implicated, and the
development of infection is associated with a poor prognosis
[45–47]. Among all hospitalized cirrhotic patients, those
admittedspeciﬁcallywithagastrointestinalhemorrhagehave
a higher rate of infection than cirrhotic patients hospitalized
for other reasons (45% versus 33%). Furthermore those with
gastrointestinal hemorrhage complicated by an uncontrolled
infection are at substantial risk of rebleeding, diﬃcult to
controlbleed,andunderlyingsepsis-associatedcoagulopathy
[48]. A meta-analyses of trials in patients with variceal
hemorrhage has shown that antibiotic prophylaxis reduced
the incidence of severe infection and decreased mortality
[49]. There has been a decrease in mortality from variceal
hemorrhage from 43% to 15% over a 20-year period, and
antibiotic prophylaxis is independently associated with im-
provedsurvival[50].Oralnorfoxacin,400mgb.d.foratleast
7 days, is recommended by the International Ascites Club
[44] and oral ciprofoxacin, 500mg b.d. for 7 days, by the
recent British Society of Gastroenterology (BSG) guidelines
[51]. The beneﬁt is greatest in those patients with more ad-
vanced liver disease. A recent RCT has shown that intra-
venous ceftriaxone (1g/day for 7 days) was more effective
than oral norﬂoxacin to prevent severe infections in patients
with advanced cirrhosis (characterized by at least two of the
following: ascites, severe malnutrition, encephalopathy, or
bilirubin >3mg/dL) and variceal bleeding [52].
2.2.3. Prophylaxis in Patients with Low Ascitic Fluid Total Pro-
tein. Ascitic ﬂuid total protein has been shown to be an
independent predictor of SBP. The risk of developing SBP
in these patients depends largely on ascites protein content.
Patients with an ascites protein >1.0g/dL will not develop
SBP in a follow-up period of 2 years, while patients with
al o w( <1.0g/dL) ascites protein have a 1-year probability
of developing SBP of around 20%. A prospective study in
cirrhotic patients during hospitalization found that 15%
of patients with ascitic protein <1.0g/dL developed SBP
compared to 2% of those with ascitic protein >1.0g/dL. The
incidence was greatest in those with Child C liver disease
and in those who did not receive short-term prophylaxis
if admitted with a gastrointestinal bleed. Two non-placebo-
controlled studies, which showed a beneﬁt of antibiotic
prophylaxis in patients with low ascites protein, included
patients with and without prior episodes of SBP and cannot
be considered as reliable determinants of primary prophy-
laxis [43, 53]. Oral norﬂoxacin administration (400mg/day)
in patients with low protein ascitic levels (<1.5g/dL) and
advanced cirrhosis or impaired renal function without prior
SBP episode reduces the probability of SBP and HRS
and improved the 3-month survival [54]. Similarly, oral
ciproﬂoxacin (500mg/day) reduces the 1-year mortality rate
in patients with ascitic protein levels <1.5g/dL and without
prior SBP episode [55].
2.3. Role of Albumin in Spontaneous Bacterial Peritonitis. In
patients with SBP, there is a risk that their systemic hemo-
dynamic parameters can deteriorate, with further arterial
and splanchnic vasodilatation. These patients are, therefore,
at high risk of developing renal insuﬃciency [56]. The devel-
opment of renal failure is the most important indicator
of reduced survival in patients with SBP compared with
patients without SBP [57]. Renal impairment develops in
approximately one-third of patients with SBP and is postu-
lated to arise as a result of a further reduction in eﬀective
arterial blood volume, mediated by vasoactive cytokines,
witharesultantincreasedrenin-angiotensin-aldosteronesys-
tem activity [58, 59]. In a multicentre randomized study,
126 patients with SBP were assigned to receive treatment
with cefotaxime alone (2g intravenously every six hours)
or cefotaxime plus intravenous albumin. The albumin was
given at a dose of 1.5g/kg in the ﬁrst 6h after diagnosis,
followed by a further infusion of 1g/kg on the third day.
With the standard treatment, renal impairment developed
in 33% of patients, whereas with the combination therapy
it occurred in only 10%. The in-hospital mortality rates were
28%and10%,respectively,[60].Asthedevelopmentofrenal
failure in cirrhotic patient with SBP carries a high risk of
morbidity and mortality, the use of albumin infusion as an
adjunctive therapy in the treatment of patients with SBP will
continue until further studies are available.4 International Journal of Hepatology
2.4. Role of Probiotics in Prevention of Spontaneous Bacterial
Peritonitis. Recent research in the use of certain probiotic
agents has shown promise in decreasing cytokine release
and improving neutrophil function in cirrhotic patients [61,
62]. The use of probiotics in this setting is attractive not
only because of its ability to modulate gut ﬂora in favor
of protective anaerobic organisms but also because of its
eﬀects in promoting gut barrier function. However, there is
no data to support decreasing infection rates or improved
outcomeswithprobioticsinthispopulation.Bacteriotherapy
with Lactobacillus has been reported to correct bacterial
overgrowth, stabilize mucosal barrier function, and decrease
bacterial translocation in rat models of acute liver injury
and failure. However, the administration of Lactobacillus
acidophilus-andLactobacillusGG-fermenteddietstoanimals
with portal hypertension and cirrhosis failed to show any
reduction in bacterial translocation or in ascites infection
rates [63, 64].
Two prospective randomized studies demonstrated the
eﬃcacy of probiotics in reducing postorthotopic liver trans-
plantation (OLT) infections [65, 66]. In the ﬁrst study, OLT
patients receiving Lactobacillus plantarum 299 and ﬁber had
less posttransplant infections than groups receiving selective
bowel decontamination. The second study used Synbiotic
2000 in post-OLT patients for 14 days and also found a
lower 30-day infection rate. Importantly, no serious adverse
eﬀects were noted in either study. As it is a cheap and feasible
alternative to selective intestinal decontamination, further
studies are needed to evaluate the eﬀect of this combination
in other cirrhotic populations.
3. UrinaryTractInfections
Urinary tract infections are the most frequent infective com-
plications in cirrhosis. As in the noncirrhotic population,
cirrhoticswithindwellingcathetersarehighlypredisposed to
develop urinary tract infections. The incidence is markedly
higher in female than in male cirrhotics [67]. Urinary
tract infections in cirrhosis are usually asymptomatic, and
bacteriuria alone is found in a high proportion of urinary
tract infections episodes in cirrhotics [68]. The majority of
infectionsarecausedbyGram-negativebacilli,and,although
urine cultures for identiﬁcation and in vitro sensitivity test-
ing of causative organisms are always recommended, cases
requiring immediate therapy should be empirically started
on a quinolone or the older but eﬀective cotrimoxazole.
These agents are very active against Gram-negative bacteria
and reach high concentrations in urine. Other antibiotic
regimes might include amoxicillin plus clavulanic acid or an
oral cephalosporin [18, 69].
4. Pneumonias
Pneumonias are the third most common infections in
patients of cirrhosis after SBP and urinary tract infections.
Community-acquired infections are the most frequent,
although hospitalized patients admitted to intensive care
units have high incidence of nosocomial pneumonias due to
predisposing factors such as tracheal intubation, esophageal
tamponade, or hepatic encephalopathy. Alcoholics are pre-
disposed to chest infections, Streptococcus pneumonia being
the causative organism in most lower respiratory tract infec-
tions [70]. A signiﬁcant number of cases of pneumonia are
caused by other pathogens normally present in the oropha-
ryngeal area, especially anaerobic bacteria or Haemophilus
inﬂuenzae,orbyGram-negativebacilli,particularlyKlebsiella
pneumoniae, mycoplasma and legionella species [70–72].
Antibiotic regimes combining macrolides and one of the
following: cefotaxime, ceftriaxone, amoxicillin-clavulanic
acid, arethe initial treatmentofchoicealthoughpiperacillin-
tazobactam or imipenem may also be used in critically ill
patients.
Hospital-acquired pneumonia is predominantly caused
by Gram-negative bacilli and staphylococci [71, 72]. Al-
though the identiﬁcation of the responsible organism in
hospital-acquired pneumonia is important for selection
of antibiotic treatment, the empiric administration of
third-generation cephalosporins (i.e., cefotaxime) should
be considered as the ﬁrst choice of antibiotic. Cirrhotic
patientswithhydrothoraxcandevelopspontaneousbacterial
empyema, which is thought to have the same pathogenesis as
SBP,sincetheirisolatedbacteriaarethesame[73].Therefore,
patientswithspontaneousbacterialempyemamaybetreated
with the same antibiotic regimens.
5. Skin and Soft TissueInfections
Soft tissue infections, particularly lymphangitis of the lower
extremities and abdominal wall, are relatively frequent in
cirrhotic patients with ankle edema or ascites. Staphylococcus
aureus and Streptococcus pyogenes are the most frequent
causative organisms [74]. Empirical antibiotic with Clox-
acillin has been considered the ﬁrst-choice antibiotic,
but, considering these causative organisms, amoxicillin-
clavulanic acid and ceftazidime may be a more adequate em-
piric antibiotic treatment. Clindamycin, vancomycin, and
teicoplanin are the other antibiotics with broad-spectrum
Gram-positive coverage.
6.Meningitis
More commonly reported in alcoholic cirrhosis with high
overall is one month case fatality rate exceeding 50%.
Streptococcus pneumoniae, Escherichia coli,a n dListeria are
the commonest pathogens implicated. Signs of meningeal
irritation including nuchal rigidity may be a delayed or even
absent clinical sign. Mortality is signiﬁcantly high and may
reach up to 80% in Child-Pugh stage C [75, 76].
7. Bacteremia and Sepsis
Patients with hepatic dysfunction have an increased risk for
bacteremia and sepsis [77]. Bacteria may enter the blood-
stream by multiple mechanisms and may quickly progress to
sepsis and multiorgan failure due to the immune dysfunc-
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may occur secondary to a preexisting infection or recent
instrumentation, this group of patients often develops spon-
taneous bacteremia. Many of these cases may be incited by
occult or overt gastrointestinal bleeding, which is known to
greatly increase the risk of bacterial infections [78]. A recent
Cochrane Database review found that the accumulated data
in eight trials demonstrated that antibiotic prophylaxis at
time of gastrointestinal hemorrhage had a signiﬁcant beneﬁt
by decreasing mortality and the incidence of bacterial infec-
tions [79]. Despite general adoption of bacterial prophylaxis,
cirrhotic patients still have a high rate of bacterial diseases,
which often progress to sepsis and severe sepsis.
Given the degree of immune dysfunction and the
morbidity of infections, patients with signiﬁcant cirrhosis
who present with, or with probable, bacteremia or sepsis
should undergo rapid diagnostic testing and should receive
intravenousantibioticsthattreatthelikelyorganismsassoon
as possible. In septic patients, early antibiotic initiation with
the appropriate agents signiﬁcantly improves outcomes, and
this eﬀect is especially important in immune-compromised
patients [80, 81].
8.Catheter-RelatedInfections
These infections are common in critically ill patients with
cirrhosis. These patients may beneﬁt from appropriate hand
hygiene, use of chlorhexidine for skin preparation, use
of full-barrier precautions during the insertion of central
venous catheters, use of the subclavian vein as the preferred
site for insertion of the catheter, and the removal of un-
necessary central venous catheters [82].
9. Conclusion
Patients with chronic liver diseases sustain impairment to
their immune systems, which worsens over time and with
disease progression. These defects in their host defense lead
to augmented risks of bacterial infections and increased
morbidity when they are incurred. Providers caring for
patients with hepatic dysfunction should have a heightened
surveillance for infectious diseases and suspect that one is
presentwithanyacutechangeinapatient’s status.With early
diagnosis and proper antibiotic treatment, the mortality of
bacterialinfectionshasdecreasedsigniﬁcantlyovertheyears.
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